News

“We are excited to establish this partnership with Acceleron as they work to advance their lead neuromuscular therapeutic candidate, ACE-083, through an ongoing Phase 2 trial in patients with CMT,” said CMTA’s CEO Amy Gray.

Amy Keller had always known about CMT as it runs in her family. But, as a healthy, active child who grew up into a symptom-free adult, it had never crossed her mind that she, too, would one day receive that ...

The CMTA announces the funding of a clinical research study that will look at pulmonary function for people who have CMT Type 2A, with the aim of developing a night-time breathing treatment similar to CPAP for CMT2A patients.

Completely funded by the CMTA, the 18-month project headed by Dr. Kleopas A. Kleopa of the Cyprus Institute of Neurology and Genetics will explore the possibility of using gene editing to treat CMT4C.

The CMTA is thrilled to announce the release of our latest professionally produced Public Service Announcement on Charcot-Marie-Tooth! Watch this beautiful piece and share it with your friends and family to spread the word.